JP5746137B2 - アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 - Google Patents
アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 Download PDFInfo
- Publication number
- JP5746137B2 JP5746137B2 JP2012501126A JP2012501126A JP5746137B2 JP 5746137 B2 JP5746137 B2 JP 5746137B2 JP 2012501126 A JP2012501126 A JP 2012501126A JP 2012501126 A JP2012501126 A JP 2012501126A JP 5746137 B2 JP5746137 B2 JP 5746137B2
- Authority
- JP
- Japan
- Prior art keywords
- arginase
- peg
- bacillus
- cys
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16386309P | 2009-03-26 | 2009-03-26 | |
| US61/163,863 | 2009-03-26 | ||
| PCT/CN2010/071357 WO2010124547A1 (en) | 2009-03-26 | 2010-03-26 | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521201A JP2012521201A (ja) | 2012-09-13 |
| JP2012521201A5 JP2012521201A5 (https=) | 2013-05-09 |
| JP5746137B2 true JP5746137B2 (ja) | 2015-07-08 |
Family
ID=42784510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012501126A Active JP5746137B2 (ja) | 2009-03-26 | 2010-03-26 | アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8507245B2 (https=) |
| EP (1) | EP2411040B1 (https=) |
| JP (1) | JP5746137B2 (https=) |
| CN (1) | CN102481345B (https=) |
| AU (1) | AU2010242422B2 (https=) |
| CA (1) | CA2756442C (https=) |
| WO (1) | WO2010124547A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382525B2 (en) * | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| WO2011008495A2 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| EP2531224B1 (en) | 2010-01-26 | 2019-06-05 | Bioregency, Inc. | Compositions and methods relating to argininosuccinate synthetase |
| US20130295073A1 (en) * | 2010-12-21 | 2013-11-07 | Bio-Cancer Treatment International Ltd. | Use of pegylated recombinant human arginase for treatment of leukemia |
| CN103184208B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 |
| US9011845B2 (en) | 2012-06-26 | 2015-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for treatment of inflammatory and infectious viral diseases |
| US8877183B2 (en) | 2012-06-26 | 2014-11-04 | National Institutes Of Health (Nih) | Methods for treatment of ocular diseases |
| CN106456723B (zh) * | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
| CN105112391B (zh) * | 2015-09-22 | 2018-07-06 | 浙江道尔生物科技有限公司 | 一种人源精氨酸酶突变体及其制备方法和用途 |
| CN106692961B (zh) * | 2015-11-17 | 2020-12-11 | 长春市福迪奥美科技有限公司 | 精氨酸酶组合物、精氨酸酶激活剂及其应用 |
| CN106434710A (zh) * | 2016-10-14 | 2017-02-22 | 江南大学 | 一种耐热精氨酸酶的基因表达序列和应用 |
| CN108265044B (zh) * | 2016-12-31 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用 |
| EP3668975A4 (en) * | 2017-08-16 | 2021-04-28 | Avalon Polytom (HK) Limited | Compositions and methods for amino acid depletion therapy |
| AU2019275733B2 (en) | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| WO2020081994A1 (en) | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| CN109793917B (zh) * | 2019-02-11 | 2020-10-09 | 海南建科药业有限公司 | 一种预防结直肠手术后吻合口瘘的凝胶的制备方法 |
| KR20220082813A (ko) | 2019-08-30 | 2022-06-17 | 아이글레아 바이오테라퓨틱스, 인크. | 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용 |
| US20210162028A1 (en) * | 2019-12-02 | 2021-06-03 | The Hong Kong Polytechnic University | Methods for Inducing Intermittent Fasting and Modulating Autophagy |
| CN115843267A (zh) * | 2020-05-14 | 2023-03-24 | 克云生物科技股份公司 | 呼吸道病毒感染的治疗 |
| WO2022063178A1 (en) * | 2020-09-23 | 2022-03-31 | The Hong Kong Polytechnic University | Fluorescent biosensor for rapid determination of l-arginine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| WO2003063780A2 (en) * | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| JP2005538709A (ja) * | 2002-06-20 | 2005-12-22 | バイオ−キャンサー・トリートメント・インターナショナル・リミテッド | アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法 |
| HK1053577A2 (en) * | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| CN1745847A (zh) * | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| WO2006058486A1 (en) * | 2004-12-03 | 2006-06-08 | Bio-Cancer Treatment International Limited | Use of arginase in combination with 5fu and other compounds for treatment of human malignancies |
| WO2011008495A2 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
-
2010
- 2010-03-26 AU AU2010242422A patent/AU2010242422B2/en active Active
- 2010-03-26 CN CN201080023256.4A patent/CN102481345B/zh active Active
- 2010-03-26 JP JP2012501126A patent/JP5746137B2/ja active Active
- 2010-03-26 WO PCT/CN2010/071357 patent/WO2010124547A1/en not_active Ceased
- 2010-03-26 US US12/732,188 patent/US8507245B2/en active Active
- 2010-03-26 EP EP10769236.0A patent/EP2411040B1/en active Active
- 2010-03-26 CA CA2756442A patent/CA2756442C/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2411040B1 (en) | 2015-09-23 |
| WO2010124547A1 (en) | 2010-11-04 |
| JP2012521201A (ja) | 2012-09-13 |
| EP2411040A4 (en) | 2012-09-12 |
| CA2756442A1 (en) | 2010-11-04 |
| US20100247508A1 (en) | 2010-09-30 |
| US8507245B2 (en) | 2013-08-13 |
| CN102481345A (zh) | 2012-05-30 |
| CA2756442C (en) | 2016-03-29 |
| CN102481345B (zh) | 2015-04-22 |
| AU2010242422B2 (en) | 2014-12-04 |
| EP2411040A1 (en) | 2012-02-01 |
| AU2010242422A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5746137B2 (ja) | アルギナーゼの部位指定的ペグ化並びにその抗がん剤及び抗ウイルス剤としての使用 | |
| US9382525B2 (en) | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents | |
| KR102442231B1 (ko) | 종양 치료를 위한 키누레닌 고갈 효소의 투여 | |
| EP2964761B1 (en) | Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment | |
| JP2024069234A (ja) | アスパラギナーゼを用いた治療法 | |
| JP2012531893A (ja) | アルギナーゼ製剤および方法 | |
| ES2987380T3 (es) | Administración de enzimas de depleción de la quinurenina para la terapia tumoral | |
| CN105531371A (zh) | 用于治疗目的的工程改造的灵长类动物l-甲硫氨酸酶 | |
| TWI827593B (zh) | 人類犬尿胺酸酶及其用途 | |
| KR20190026813A (ko) | 시스틴의 인간-효소 매개된 고갈 | |
| EP2721057B1 (en) | Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer | |
| EP2196477B1 (en) | Modified recombinant human endostatin and its application | |
| CN102724980B (zh) | 蛋白-聚合物偶联物的治疗用途 | |
| EA020347B1 (ru) | Пептид-полимерные конъюгаты | |
| WO2024020366A1 (en) | Broad spectrum nanozymes | |
| HK1176015B (en) | Therapeutic use of protein-polymer conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150409 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5746137 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |